Page 1

Publisher: Renub Research Published: June 2010


Report Details “Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering: 

Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast

Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence

Region wise Diabetes Health Expenditure and Mortality

Top 10 Countries Diabetes Population and Future Forecast

Top 5 Countries Diabetes Drug Market and Future Forecast

Top 7 Countries Insulin Market and Future Forecast

Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market

Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market

Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market

Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market

Research Highlights 

USA controls more than 50% of the total Diabetes Drug market share in 2009

Global Insulin Market is estimated to reach around US$ 17 Billion by 2013

China will have the second highest Insulin market share by 2012 replacing Germany

DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015

GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015

Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.

© Renub Research

Page 2 of 10


Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030.

Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US$ 4 Billion by 2017

Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists

China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009

Japan Insulin market is expected to be more than US$ 1 Billion by 2010

Key Drugs Analyzed Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus, GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide Data Sources Information and data in this report has been collected from various printable and nonprintable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.

© Renub Research

Page 3 of 10


Table of Contents 1.

Executive Summary

2.

Global Diabetes Market 2.1

Global – Diabetes Drug Market & Future Forecast

2.2

Global – Insulin Market & Future Forecast

2.3

Global – Diabetes Drug Market Share & Future Forecast of (Brazil, China, Japan, USA, India)

2.4

Global – Insulin Market Share & Future Forecast of (Mexico, Germany, Russia, China, Japan,

USA, India)

3.

4.

2.5

Global – Dipeptidyl Peptidase (DPP – IV) Inhibitors Market & Future Forecast

2.6

Global – Glucagon-like Peptide-1(GLP-1) Market & Future Forecast

Global – Top 6 Diabetes Drug Brands Market Performance 3.1

Avandia – Past & Present Market

3.2

Actos – Past, Present & Future Forecast

3.3

Amaryl – Past, Present & Future Forecast

3.4

Avandamet – Past, Present & Future Forecast

3.5

Prandin/Novonorm – Past & Present Market

3.6

Starlix – Past, Present & Future Forecast

Global – Top 9 Insulin Brands Market Performance 4.1

Novomix – Past, Present & Future Forecast

4.2

Novorapid – Past, Present & Future Forecast

4.3

Levemir – Past, Present & Future Forecast

4.4

Degludec – Yet to be Launched - Future Forecast

4.5

Degludecplus – Yet to be Launched – Future Forecast

4.6

Humalog – Past & Present Market

4.7

Humulin – Past & Present Market

4.8

Apidra – Past, Present & Future Forecast

4.9

Lantus – Past, Present & Future Forecast

© Renub Research

Page 4 of 10


5.

6.

7.

Global – DPP-IV Inhibitors Brands Market Performance 5.1

Januvia – Past, Present & Future Forecast

5.2

Onglyza – Past, Present & Future Forecast

5.3

Alogliptin – Yet to be Launched – Future Forecast

5.4

Galvus – Past, Present & Future Forecast

5.5

DPP-IV Inhibitors – In Trial Phases

Global – GLP-1 Agonists Brands Market Performance 6.1

Byetta – Past, Present & Future Forecast

6.2

Victoza – Past, Present & Future Forecast

6.3

Exenatide LAR – Yet to be Launched – Future Forecast

6.4

Syncria – Yet to be Launched – Future Forecast

6.5

Taspoglutide – Yet to be Launched – Future Forecast

Regional Estimates for Diabetes 7.1

Diabetes – Population & Prevalence

7.2

Impaired Glucose Tolerance (IGT) – Population & Prevalence

7.3

Mortality – Due to Diabetes

7.4

North America & Caribbean Region

7.4.1

Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence

7.4.2

Healthcare Expenditure & Type 1 Diabetes

7.4.3

Mortality

7.5

Middle East and North African Region

7.5.1

Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence

7.5.2

Healthcare Expenditure & Type 1 Diabetes

7.5.3

Mortality

7.6

South-East Asian Region

7.6.1

Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence

7.6.2

Healthcare Expenditure & Type 1 Diabetes

7.6.3

Mortality

7.7

European Region

7.7.1

Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence

7.7.2

Healthcare Expenditures & Type 1 Diabetes

© Renub Research

Page 5 of 10


7.7.3 7.8

South and Central American Region

7.8.1

Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence

7.8.2

Healthcare Expenditures & Type 1 Diabetes

7.8.3

Mortality

7.9

Western Pacific Region

7.9.1

Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence

7.9.2

Healthcare Expenditures & Type 1 Diabetes

7.9.3

Mortality

7.10

8.

Mortality

African Region

7.10.1

Diabetes & Impaired Glucose Tolerance (IGT) – Population & Prevalence

7.10.2

Healthcare Expenditure & Type 1 Diabetes

7.10.3

Mortality

Global – Top 10 Diabetic Countries Performance 8.1

Number of People in Top 10 Diabetic Place

8.2

Prevalence of Diabetes in Top 10 Countries

8.3

India

8.3.1

Diabetes Population & Future Scenario

8.3.2

India – Diabetes Drug Market & Future Forecast

8.3.3

India-Insulin Market & Future Forecast

8.4

China

8.4.1

Diabetes Population & Future Scenario

8.4.2

Diabetes Drug Market & Future Forecast

8.4.3

China Insulin Market & Future Forecast

8.5

United States

8.5.1

Diabetes Population & Future Scenario

8.5.2

Diabetes Drug Market & Future Forecast

8.5.3

Insulin Market & Future Forecast

8.6

Brazil

8.6.1

Diabetes Population & Future Scenario

8.6.2

Diabetes Drug Market & Future Forecast

8.7

Russia

8.7.1

Diabetes Population & Future Scenario

8.7.2

Insulin Market & Future Forecast

© Renub Research

Page 6 of 10


8.8

Japan

8.8.1

Diabetes Population & Future Scenario

8.8.2

Diabetes Drug Market & Future Forecast

8.8.3

Insulin Market & Future Forecast

8.9

Germany

8.9.1

Diabetes Population & Future Scenario

8.9.2

Insulin Market & Future Forecast

8.10

Mexico

8.10.1

Diabetes Population & Future Scenario

8.10.2

Insulin Market & Future Forecast

8.11

Indonesia

8.11.1 8.12

Diabetes Population & Future Scenario

Pakistan

8.12.1

Diabetes Population & Future Scenario

Š Renub Research

Page 7 of 10


Order Form Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780 Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to info@renub.com

Format Report Title: Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

Single User (Email from Publisher)

Hard Copy (Mail Delivery)

CD – Rom (Mail Delivery)

Global Site License (Multiple User License)

US$ 1,100

US$ 1,250

US$ 1,250

US$ 1,600

For ordering this report: Three easy ways to place your order: 1) Order online by Credit Card (Visa, MasterCard, etc.): http://www.renub.com/report/global-diabetes-market-trends-future-forecast---diabetesdrug-anti-diabetic-drug-insulin-dpp-iv-glp-1-27 2) Order by Wire Transfer: http://www.renub.com/report/wiretransfer.aspx?id=27&pid=1092 To pay by Wire Transfer, please, fill in your contact details in the form below:

© Renub Research

Page 8 of 10


Bank Details Account Name: Renub Research A/C No.: 109102000023296 Name of Bank: IDBI Bank Ltd. Swift Code: IBKLINBB010 Bank Address: 4th Floor Indian Red Cross Building 1 Red Cross Road Opposite Parliament Street New Delhi – 110001 India

Contact Information First Name:

Last Name:

Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message:

© Renub Research

Page 9 of 10


3) Order by Check Please post the check accompanied by this form, to: Company Address: Renub Research 1st Floor C-86, Sector -10 Noida - 201301 Uttar Pradesh India Phone: +91-120-4219-822, 4249-780

For free Sample copy report or to view any of our sample work please contact us at info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)

Follow Us Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090 LinkedIn: http://www.linkedin.com/company/renub-research Twitter: http://twitter.com/RenubResearch

Š Renub Research

Page 10 of 10

Global diabetes market trends & future forecast – diabetes drug (anti diabetic drug), insulin, dpp i  

Renub Research (http://www.renub.com/report/global-diabetes-market-trends-future-forecast---diabetes-drug-anti-diabetic-drug-insulin-dpp-iv-...

Read more
Read more
Similar to
Popular now
Just for you